Workflow
MacroGenics(MGNX)
icon
Search documents
MacroGenics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX
GlobeNewswire News Room· 2024-08-13 16:34
Core Viewpoint - MacroGenics, Inc. is facing a class action lawsuit due to alleged material misrepresentations regarding the safety data of its drug vobramitamab duocarmazine, leading to a significant stock decline of 77.4% [2][3]. Group 1: Class Action Details - The class period for the lawsuit is from March 7, 2024, to May 9, 2024 [2]. - The stock price of MGNX dropped by $11.36 per share following the revelation that the drug was more dangerous than previously claimed [2]. - Shareholders are encouraged to register for the class action by September 24, 2024, to potentially become lead plaintiffs [3]. Group 2: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].
MGNX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
GlobeNewswire News Room· 2024-08-13 04:45
Core Viewpoint - MacroGenics, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, primarily related to misleading statements about the safety profile of its drug vobramitamab duocarmazine during its clinical trials [1][4]. Company Overview - MacroGenics is a biopharmaceutical company focused on developing monoclonal antibody-based therapeutics for cancer treatment [3]. Allegations and Impact - The class action lawsuit claims that MacroGenics and its CEO made false or misleading statements regarding the safety of vobramitamab duocarmazine, particularly during the TAMARACK Phase 2 study [4]. - On May 9, 2024, interim data revealed that the adverse event rate for vobra duo was over 98.9% and 100% for dosages of 2.0 mg/kg and 2.7 mg/kg, respectively, with over 50% of adverse events being grade 3 or greater. Additionally, there were five fatalities linked to the study, three of which are under investigation [5]. - Following the release of this data, MacroGenics' stock price plummeted by more than 77% [5]. Legal Process - Investors who purchased MacroGenics stock or sold puts during the class period (March 7, 2024, to May 9, 2024) can seek to be appointed as lead plaintiff in the class action lawsuit, with a deadline of September 24, 2024 [1][6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud cases, having recovered $6.6 billion for investors in class action cases, significantly more than any other firm in recent years [7].
The Gross Law Firm Notifies Shareholders of MacroGenics, Inc.(MGNX) of a Class Action Lawsuit and an Upcoming Deadline
Prnewswire· 2024-08-12 09:30
NEW YORK, Aug. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=94748&from=4 CLASS PERIOD: March 7, 2024 ...
Class Action Announcement for MacroGenics, Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against MacroGenics, Inc. - Contact Kessler Topaz Meltzer & Check, LLP
GlobeNewswire News Room· 2024-08-09 21:00
RADNOR, Pa., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period"). The lead plaintiff deadline is September 24, 2024. CONT ...
ROSEN, A LEADING NATIONAL FIRM, Encourages MacroGenics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MGNX
GlobeNewswire News Room· 2024-08-09 17:26
NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"), of the important September 24, 2024 lead plaintiff deadline. SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...
MGNX Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges MGNX Investors with Losses to Contact the Firm
Prnewswire· 2024-08-09 03:45
RADNOR, Pa., Aug. 8, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the "Class Period" The lead plaintiff deadline is September 24, 2024. CONTACT KES ...
MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit – Hagens Berman
GlobeNewswire News Room· 2024-08-08 15:31
SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 – May 9, 2024 Lead Plaintiff Deadline: Sept. 24, 2024 Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916-0895 Class Action Lawsuit Against MacroGenics, Inc. (MGNX): MacroGenics, Inc. shares plummeted on July 31 after the biotechnology company announced it was halting a mid-s ...
Kirby McInerney LLP Reminds MacroGenics, Inc. (MGNX) Investors of Class Action Filing and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2024-08-07 21:46
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Maryland on behalf of those who acquired MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) securities during the period of March 7, 2024 to May 9, 2024, inclusive ("the Class Period"). Investors have until September 24, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. [Click here ...
MacroGenics, Inc. Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against MGNX
GlobeNewswire News Room· 2024-08-07 20:31
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. For more information, submit a form, email a ...
MacroGenics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 24, 2024 to Discuss Your Rights – MGNX
GlobeNewswire News Room· 2024-08-07 17:12
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=94047&from=3 CLASS PERIOD: March 7, 2 ...